Low prevalence of Cfr-mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy

Data de publicació

2016-04-13T15:13:41Z

2016-04-13T15:13:41Z

2013

2016-04-13T15:13:46Z

Resum

Linezolid is an effective antimicrobial agent to treat methicillin-resistant Staphylococcus aureus (MRSA). Resistance to linezolid due to the cfr gene is described worldwide. The present study aimed to analyze the prevalence of the cfr-mediated linezolid resistance among MRSA clinical isolates in our area. A very low prevalence of cfr mediated linezolid resistance was found: only one bacteremic isolate out of 2 215 screened isolates. The only linezolid resistant isolate arose in a patient, previously colonized by MRSA, following linezolid therapy. Despite the low rate of resistance in our area, ongoing surveillance is advisable to avoid the spread of linezolid resistance.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

Public Library of Science (PLoS)

Documents relacionats

Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0059215

PLoS One, 2013, vol. 8, num. 3

http://dx.doi.org/10.1371/journal.pone.0059215

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

cc-by (c) Sierra, J.M. et al., 2013

http://creativecommons.org/licenses/by/3.0/es

Aquest element apareix en la col·lecció o col·leccions següent(s)